Pharmacological activation of cGAS-STING pathway to reverse cancer drug resistance

Pharmacology and Therapeutics · Published 2026-02-01 · DOI 10.1016/j.pharmthera.2026.108991

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.pharmthera.2026.108991

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• The aftermath of alcohol misuse: Linking cellular damage, suboptimal micronutrient nutrition, and organ dysfunction · Pharmacology and Therapeutics · 2026 · Same journal
• A dive into the untapped potential of marine compounds in counteracting neurodegeneration · Pharmacology and Therapeutics · 2026 · Same journal
• Mathematical modeling of T cell exhaustion in the tumor microenvironment · Pharmacology and Therapeutics · 2026 · Same journal
• C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy · Pharmacology and Therapeutics · 2026 · Same journal
• Circular RNA serves as an upstream regulator of the miRNA//ABCC1 axis in human cancers · Pharmacology and Therapeutics · 2026 · Same journal
• Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk · Pharmacology and Therapeutics · 2026 · Same journal
• Therapeutic potential of targeting novel signaling pathways in regulating chronic inflammation in obstructive lung disorders · Pharmacology and Therapeutics · 2026 · Same journal
• Incretin-based therapies: Effects on plasma lipids and potential mechanisms · Pharmacology and Therapeutics · 2026 · Same journal
• RNA renaissance: Harnessing non-coding RNA therapeutics for hepatocellular carcinoma · Pharmacology and Therapeutics · 2025 · Same journal
• SGLT2 inhibitors: Do they have antiarrhythmic properties? · Pharmacology and Therapeutics · 2026 · Same journal